10Turner R, Cull C, Holman R, UKPDS 17: A 9 - year update of arandomized, controlled trial on the effect of improved metabolic control on complications in NIDDM. Ann Intern Med1996,124:136.
4SILINK M. Fore Word of (Diabetes Atlas) [M/OL]. Belgium: International Diabetes Federation, 2009-08-05. http://ww.eatlas. Idf org/ nersc269· html, accessed Aug.
5MARTIM A G, SANDERS R A, WATKINS J. Diabetes, oxidative stress, and antioxidant: a review[J]. J Biochem Mol Toxical, 2003, 17 (1): 24-38.
6MOHAMED A K, BIERHAUS A, SCHIEKOFER S, et al. The role of oxidative stress and NF (B) activation in later diabetic complication[J]. Biofactors, 1999, 10: 175-179.
7WHITE J R, CAMPBELL R K. Diabetes mellitus[M]//HERFINDAL E T, GOURLEY D R. Textbook of therapeutics: drug and disease management [M]. 6th ed. Baltimore: Williams and Wilkins, 1996: 357- 385.
8Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. New England Journal of Medicine, 1993, 329: 977-986.
9de FRONZO R A. Pharmacologic therapy for type 2 diabetes mellitus[J]. Annals of Internal Medicine, 1999, 131: 281-303.
